<SEC-DOCUMENT>0001193125-23-069551.txt : 20230314
<SEC-HEADER>0001193125-23-069551.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314060526
ACCESSION NUMBER:		0001193125-23-069551
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230314
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23729096

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d476905d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated March 14, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d476905dex991.htm">Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March 14, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d476905dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g476905dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Initiation of Phase II/III Trial for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Integrated Phase II/III trial design incorporates feedback from the FDA and EMA and will help inform a BLA and
MAA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">HR+/HER2-neg/low</FONT> metastatic breast cancer (MBC) patient population has
been expanded to include triple-negative breast cancer, which together account for ~78% of breast cancer cases </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval for study start received in US and IRB approval in Spain, with more countries to follow shortly
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First patient expected to be enrolled in early Q2 CY2023 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> APC
activator, efti is well positioned to enhance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy in MBC </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 14</B><B></B><B>&nbsp;March 2023 &#150;</B> I<U>mmutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announced the initiation of
<FONT STYLE="white-space:nowrap">AIPAC-003</FONT> (<B>A</B>ctive <B>I</B>mmunotherapy, Eftilagimod Alpha, and <B>PAC</B>litaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (&#147;efti&#148;) in combination with paclitaxel for
the treatment of metastatic <FONT STYLE="white-space:nowrap">HER2-neg/low</FONT> breast cancer (MBC). Regulatory approval has been received in the US and Institutional Review Board (IRB) approval has been received in Spain, with approvals in
additional countries anticipated to follow shortly. The first patient is expected to be enrolled in early Q2 CY2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein targeting MHC Class&nbsp;II ligands on antigen-presenting cells (APC), efti is uniquely
positioned to improve clinical outcomes from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy. Its activation of APCs (e.g., dendritic cells, monocytes) triggers a broad immune response
that includes significant increases in cytotoxic CD8+ T cells armed with chemo-induced tumour antigens to target cancer. This synergy was demonstrated by the AIPAC Phase IIb trial&#146;s encouraging efficacy and safety, including a <FONT
STYLE="white-space:nowrap">+2.9-month</FONT> median overall survival (mOS) improvement, statistically significant mOS improvements between 4.2 to 19.6 months across three <FONT STYLE="white-space:nowrap">pre-specified</FONT> subgroups, a
statistically significant increase in cytotoxic CD8 T cells that correlated with improved OS, a higher 48% ORR (vs 38% for chemo alone), and a superior Quality of Life preservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, said: &#147;With its novel mechanism of action to activate antigen-presenting cells, efti has to date safely improved clinical
outcomes from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-(L)1</FONT></FONT> therapies and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy. We look forward
to <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> building upon the encouraging synergy seen in our previous Phase IIb trial in metastatic breast cancer, especially with its three key adaptations: same day administration of efti plus paclitaxel,
this dual <FONT STYLE="white-space:nowrap">IO-chemotherapy</FONT> treatment continuing until disease progression, and a new primary endpoint of overall survival. The selected Phase II/III trial design allows us to move forward with a risk-balanced
approach in MBC, as we continue our prioritized late-stage clinical development with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in 1st line head&nbsp;&amp; neck squamous cell carcinoma and 1st
line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company and the US Food and Drug Administration (FDA) agreed to the
integrated Phase II/III trial design for <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> that will help inform a Biologics License Application (BLA). Additionally, the trial design incorporates feedback from Scientific Advice meetings with the
European Medicines Agency (EMA) to support a Marketing Authorisation Application (MAA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g476905dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on feedback from the FDA/EMA, the <FONT STYLE="white-space:nowrap">HR+/HER2-neg/low</FONT> MBC patient
population has been expanded to include triple-negative breast cancer (TNBC), an aggressive cancer with limited treatment options, which together account for ~78% of breast cancer cases. The Company and the FDA also agreed to an open-label <FONT
STYLE="white-space:nowrap">lead-in</FONT> component of 6 to 12 patients to test 90mg efti dosing in combination with paclitaxel driven by efti&#146;s excellent safety profile, along with the&nbsp;<U>FDA&#146;s Project Optimus&nbsp;initiative</U> in
oncology. Additionally, patients will receive <FONT STYLE="white-space:nowrap">same-day</FONT> administration of efti + paclitaxel that can continue until disease progression, unlike the prior AIPAC trial that administered both on different days and
stopped chemotherapy at six months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The open-label <FONT STYLE="white-space:nowrap">lead-in</FONT> of up to 12 patients will be followed by a randomized
(1:1) portion of the Phase II consisting of up to 58 patients that will receive 30mg efti or 90mg efti to determine the optimal biological dose in combination with paclitaxel. Depending on the Phase II results, potential regulatory actions and
resources, a randomized, double-blinded, placebo-controlled Phase III portion will then follow. The Phase III will have overall survival as the primary objective and may include a specific patient population. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the late-stage clinical development of efti, the Phase II portion of the MBC trial, the ongoing randomized/controlled Phase II trial in 1st
line HNSCC, and the initiation of the registrational trial in 1st line NSCLC are included in the budget and have no impact on the Company&#146;s expected cash runway to the end of the 1st half of calendar year 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen-presenting cell (APC) activator that
stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen presenting cells via MHC II molecules leading to expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic
cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-y</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and HER2&#150;/HR+ metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT>
immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g476905dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris
Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g476905dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g476905dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MNG4A5@ITFI0ELU_6GH:0_E^E7L:+\@H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@!"<?A_D4 ?%&M_M'>-]/^/47PVM_"=G+X>_M^PT,JUOJ
M(UVXM[MX(I-;MYUF$(@C,QF1?LKH8806D!)EB /M9,[1G@]_:@!U !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU:TA$]QI-_L$X@#*AN+:6(F.YA5V56*D,A9=Z*&4GOPF,HXN/N/EDE?EO?\
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M[6RW#7=Q>7D @4&ZBQL64D;CMXH ^;Y?V[=+27%M\-[^6'/WYO$]M;R[0?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 U^GXC^=-;K^N@UU]&?FUXA_P"2^3_]E#L?_3I:U\M7_P"1
ME5_QK\S\FQ/_ "4;_P"PB/\ Z4>X?M4_\@#PG_V%KW_TC6N_.?X5'^NA]'QO
M_N-#_K['_P!-5#T#]G3CX7:/[7FL_P#ISN*Z<M_W2E_B_P STN%M,GI^K_4^
M:OVF?^2EK_V+VE?I/J%>9F/^^4_(^2XO7_"OAG_T[_\ ;D?=GAC_ )%OP_\
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M3W\>H:R$=60BVU74KJ[L6VL,@/8O;OC_ &_S-O(-O(^@: "@ H * "@ H *
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MEHSC('!Z5[%.+4(K9Q6WX'UE"E.G0I0:7-3@HVOV26]M-CY6A^!OC"+XI?\
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M0+B/(+@=>37BT<!5HXM5V_=C)R2M:]^A\9AN',90S=8V<H^SYW)):_C?]#Z
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H 0\#TQ^'3_ZU&WR$UTVMVT,S3=3M-52XDLV=DM+^_TV4NC)BZTZYDM+
ME5#?>0312 ,.#MR*%=/?3M;]02MLVK=R"'7=-FURZ\.)/_Q-+.QAU*6#8X4V
MTLIB^27;L>6)C TL:L6C6]M&8 7"9+V\@L]-=NVAG-XKM3J5SIMCIVK:J^GW
M*6>I7.GVL3V6G7,BQ2+#/-<7,1N)5AGADD2S6Z:%95\U4)P!V>EMAV5[ZJW2
M^GW'1SS"W@><QR-LC,GE0H7F?:I;RXT4_/(<851U.!WH=^CM;YBL]F]%\C'T
M37K?6I+^W6UOM/O=*GBM[^PU!(DN;=Y[>*[MFW6T\T$T4MM-&X>&:0 [D8AT
M95=[?(7)%=U;S+AU6U75ET7+_;6T^34U4H?+^R17,=H[>9TWB611MZXYZ4M>
M^G:UAI-;-Z=]3F1\0_"__"(W'C4WCC0;03":4VTXNEDAN?L8@6QV><9Y)]@B
M4)^\$T3H3'(KE)<JM<:T]>^QL2^)M)M]>L?#<LS+JNI:=<ZG90E'\J:VM'1)
M%6X ,8N2&=TAW;W2WG=05A<BK_*PE%1>EU\R@GC?0&L_%5^EQ(]KX,GO+;7)
M(H9&\J;3]/BU&]6U^4"\$44C1,T18">WFB)#1-A._32WS_R#7J]NVAN/JUI%
MJMEHS&07M_8:CJ5NH5C']DTJXTNVO&:3HCK+K%B G4B1B/NT[V^0N1+J]/,P
M;#QUX>U'3/[6L[F62T77+7PZZM;S1W-OJMYJEOI%O!<6TJ*\*/<W5M(LA!5X
M)XYD+1NI9*ZZ[;:6'9K9M6[ZEB_\6V=E?SZ9;:?JVL7EE!#<:C%I%HEP-.@N
M-Q@-U)-/"C3NB.ZVL+2W)0*XAVNA<_0>WJB&_P#&^EV6B6_B.*VU+4]%N+87
M:WNFVR2B"W)10UU!<3030/O<(8C&9$9761$9&  -6/7K<W.E64UM>6=YJUO?
M7%O:W,2K+&FG>1]H%PT,DD<3C[3%@"1LY//% %.[\7:79V%]?F.\GCT_6[7P
M[+%;P;KA]5O-1L-*MK>".1T$BO>ZG9H'+*,2$G 4T .N?%$%CI$FL7NF:M:1
MQWEE8I9S06YOI[C4;ZTTVR6&**Z>,K+>7L"!FE11EBQ55S0!:T;Q!::S)?VT
M4%[97VER01W^GZA;FWNK;[3$9K:3Y6>*>"6,,5E@EEC+1R)NWQNJ@#="\2Z5
MXB.J+IDSR'1]2FTN[WQ2P_OX ,RV_FHOVBS<EA'<1[HI#%($8F-L &1IOCO2
M]1FTZ);+5K1-8^TC1+F\L]EIJS6EO<7<L=G/#)*$F-K:W,R17/V>1XX'=%(1
MMH!H6'BS2-2.BK922S/KMO=W5G$(G6:"WL!&M\]_$P#6)M[F6&UD23#I<3)$
MRA@^P ^#OV[?^0C\-?\ KR\4_P#H[0Z /JW]G7_DBGP\_P"P&?\ TOO: /:J
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#QH?'[X5?\ 0T)Q
M_P!0K7/_ )65PK,<)_S\M8\'_63*4E^__ /^%_?"G_H:%_\ !5KG_P K*?\
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M /@'_"_OA3_T-"_^"K7/_E91_:.#_P"?OX!_K)E/_/\ _ /^%_?"G_H:%_\
M!5KG_P K*/[1P?\ S]_ /]9,I_Y__@'_  O[X4_]#0O_ (*M<_\ E91_:.#_
M .?OX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\
MG_\ @'_"_OA3_P!#0O\ X*M<_P#E91_:.#_Y^_@'^LF4_P#/_P# /^%_?"G_
M *&A?_!5KG_RLH_M'!_\_?P#_63*?^?_ . ?\+^^%/\ T-"_^"K7/_E91_:.
M#_Y^_@'^LF4_\_\ \ _X7]\*?^AH7_P5:Y_\K*/[1P?_ #]_ /\ 63*?^?\
M^ ?\+^^%/_0T+_X*M<_^5E']HX/_ )^_@'^LF4_\_P#\ _X7]\*?^AH7_P %
M6N?_ "LH_M'!_P#/W\ _UDRG_G_^ ?\ "_OA3_T-"_\ @JUS_P"5E']HX/\
MY^_@'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?
M_P" ?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\
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MX!_K)E/_ #__  #_ (7]\*?^AH7_ ,%6N?\ RLH_M'!_\_?P#_63*?\ G_\
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M'^LF4_\ /_\  /\ A?WPI_Z&A?\ P5:Y_P#*RC^T<'_S]_ /]9,I_P"?_P"
M?\+^^%/_ $-"_P#@JUS_ .5E']HX/_G[^ ?ZR93_ ,__ , _X7]\*?\ H:%_
M\%6N?_*RC^T<'_S]_ /]9,I_Y_\ X!_PO[X4_P#0T+_X*M<_^5E']HX/_G[^
M ?ZR93_S_P#P#_A?WPI_Z&A?_!5KG_RLH_M'!_\ /W\ _P!9,I_Y_P#X!_PO
M[X4_]#0O_@JUS_Y64?VC@_\ G[^ ?ZR93_S_ /P#_A?WPI_Z&A?_  5:Y_\
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MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_
M]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#
M_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G
M_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @
M_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&
M5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G
M_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ
M!_WQJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQ
MJ/\ \C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\
M\C4?V)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?
MV)7_ )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_
M )X?>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?
M>_\ (/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\
M(/\ 4G$_]!=#_P G_P @_P"&5O%G_0QZ!_WQJ/\ \C4?V)7_ )X?>_\ (/\
M4G$_]!=#_P G_P C[H?J*^BAU/T<95@% !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
: % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
